In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. It is currently approved for use in non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA). Rituximab is non-mutagenic, associated with low treatment-related toxicity, and few, if any, long term adverse events, making it an attractive agent to be tried in off-label settings like Hodgkin lymphoma (HL). HL consists of two distinct subtypes - classic HL (cHL) and lymphocyte predominant HL (LPHL). CD20 is present in virtually all patients with LPHL, and in a significant minority of patients with cHL. In this CD20 positive sub-population, the use of rituximab is a rational intervention strategy. Rituximab has been used in patients with cHL as well as LPHL with good efficacy. In this article, we provide a clinically-oriented overview of the use of rituximab in the different sub-types of HL, and report updated results of our series of 8 LPHL patients treated with rituximab. A systematic review of the literature is also presented.

Rituximab in Hodgkin lymphoma: is the target always a hit? / K. Saini, A.H. Jr, E. Cocorocchio, A. Vanazzi, M. Saini, P. Raviele, G. Pruneri, F. Peccatori. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 37:5(2011 Aug), pp. 385-390.

Rituximab in Hodgkin lymphoma: is the target always a hit?

G. Pruneri
Penultimo
;
2011

Abstract

In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. It is currently approved for use in non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and rheumatoid arthritis (RA). Rituximab is non-mutagenic, associated with low treatment-related toxicity, and few, if any, long term adverse events, making it an attractive agent to be tried in off-label settings like Hodgkin lymphoma (HL). HL consists of two distinct subtypes - classic HL (cHL) and lymphocyte predominant HL (LPHL). CD20 is present in virtually all patients with LPHL, and in a significant minority of patients with cHL. In this CD20 positive sub-population, the use of rituximab is a rational intervention strategy. Rituximab has been used in patients with cHL as well as LPHL with good efficacy. In this article, we provide a clinically-oriented overview of the use of rituximab in the different sub-types of HL, and report updated results of our series of 8 LPHL patients treated with rituximab. A systematic review of the literature is also presented.
Classic Hodgkin lymphoma; Lymphocyte predominant Hodgkin lymphoma; Rituximab; Anti-CD20 monoclonal antibodies; Targeted therapy
Settore MED/08 - Anatomia Patologica
ago-2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0305737210001957-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 683.02 kB
Formato Adobe PDF
683.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/297287
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 31
social impact